Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N plus ), ER-positive breast cancer patients (pts): Results from NSABP B-28

被引：4
|
作者：
Mamounas, E. P.
Tang, G.
Paik, S.
Baehner, F. L.
Liu, Q.
Jeong, J-H
Kim, S-R
Butler, S. M.
Jamshidian, F.
Cherbavaz, D. B.
Sing, A. P.
Shak, S.
Julian, T. B.
Lembersky, B. C.
Wickerham, D. L.
Costantino, J. P.
Wolmark, N.
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, Operat Ctr, Pittsburgh, PA USA
[2] Natl Surg Adjuvant Breast & Bowel Project, Biostat Ctr, Pittsburgh, PA USA
[3] Aultman Hosp, Canton, OH USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA
[5] Genom Hlth Inc, Redwood City, CA USA
[6] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
[7] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-S1-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-10
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada
    Torres, S.
    Trudeau, M.
    Gandhi, S.
    Warner, E.
    Verma, S.
    Pritchard, K.
    Petrella, T.
    Slodkowska, E.
    Hew-Shue, M.
    Chao, C.
    Eisen, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer.
    Oratz, R.
    Chao, C.
    Skrzypczak, S.
    Ory, C.
    Broder, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
    Hassan, Saima
    Younan, Rami
    Patocskai, Erica
    Provencher, Louise
    Poirier, Brigitte
    Sideris, Luca
    Dube, Pierre
    Mihalcioiu, Catalin
    Chabot-Blanchet, Malorie
    Guertin, Marie-Claude
    Boileau, Jean-Francois
    Robidoux, Andre
    ONCOLOGIST, 2022, 27 (10): : 822 - 831
  • [34] Breast cancer-specific survival in >4,600 patients with lymph node-positive (LN plus ) hormone receptor-positive (HR plus ) invasive breast cancer (BC) and 21-gene recurrence score® (RS) results in the SEER registries
    Miller, D. P.
    Roberts, M.
    Petkov, V. I.
    Shak, S.
    Howlader, N.
    Cronin, K.
    Penberthy, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
    Weiser, Roi
    Haque, Waqar
    Polychronopoulou, Efstathia
    Hatch, Sandra S.
    Kuo, Yong-fang
    Gradishar, William J.
    Klimberg, V. Suzanne
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 667 - 676
  • [36] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
    Roi Weiser
    Waqar Haque
    Efstathia Polychronopoulou
    Sandra S. Hatch
    Yong-fang Kuo
    William J. Gradishar
    V. Suzanne Klimberg
    Breast Cancer Research and Treatment, 2021, 185 : 667 - 676
  • [37] The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
    Salomon M. Stemmer
    Shmuel H. Klang
    Noa Ben-Baruch
    David B. Geffen
    Mariana Steiner
    Lior Soussan-Gutman
    Shahar Merling
    Christer Svedman
    Shulamith Rizel
    Nicky Lieberman
    Breast Cancer Research and Treatment, 2013, 140 : 83 - 92
  • [38] The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
    Stemmer, Salomon M.
    Klang, Shmuel H.
    Ben-Baruch, Noa
    Geffen, David B.
    Steiner, Mariana
    Soussan-Gutman, Lior
    Merling, Shahar
    Svedman, Christer
    Rizel, Shulamith
    Lieberman, Nicky
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (01) : 83 - 92
  • [39] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Naoi, Yasuto
    Kishi, Kazuki
    Tsunashima, Ryo
    Shimazu, Kenzo
    Shimomura, Atsushi
    Maruyama, Naomi
    Shimoda, Masafumi
    Kagara, Naofumi
    Baba, Yosuke
    Kim, Seung Jin
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 299 - 306
  • [40] Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients
    Yasuto Naoi
    Kazuki Kishi
    Ryo Tsunashima
    Kenzo Shimazu
    Atsushi Shimomura
    Naomi Maruyama
    Masafumi Shimoda
    Naofumi Kagara
    Yosuke Baba
    Seung Jin Kim
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2013, 140 : 299 - 306
12345